Loading clinical trials...

Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias | Clinical Trials | Clareo Health

RECRUITING

Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias

NCT06306963•Mayo Clinic

View on ClinicalTrials.gov

Summary

The researchers are trying to find out more about Gastric Antral Vascular Ectasia (GAVE). This is a condition that affects the blood vessels in the stomach, leading to their enlargement and possible bleeding. It can also cause symptoms such as abdominal pain and nausea. By participating in this study, you will help us learn how often these symptoms occur and how they relate to stomach functioning.

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients \>18 years of age with endoscopic evidence of Gastric Antral Vascular Ectasia.
•Willingness to participate in the study
•Capacity to provide informed consent.
•No evidence of organic, systemic, or metabolic disease (e.g. diabetes mellitus) to explain the symptoms on routine investigations

Exclusion Criteria

•Patients with transfusion dependent blood loss.
•Patients with severe decompensated liver disease.
•Patients with end stage renal disease.
•Presence of other diseases (structural or metabolic) which could interfere with interpretation of the study results.
•Pregnant or lactating women.
•Patients who have not had a CBC and differential blood draw completed within the last six months.
•Current heavy alcohol use.

Locations (1)

Mayo Clinic

Rochester, Minnesota, United States

Key Dates

Start Date

March 22, 2024

Primary Completion Date

September 1, 2026

Completion Date

September 1, 2026

Last Updated

March 4, 2026

Enrollment

ESTIMATED participants

Conditions

Gastric Antral Vascular EctasiaCirrhosisChronic Kidney Disease

Interventions

Gastric Emptying Breath Test

DIAGNOSTIC_TEST

Contacts

Taylor N Hines

CONTACT

507-538-9959 hines.taylor@mayo.edu

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

NCT07241390

Atherosclerosis Cardiovascular DiseaseChronic Kidney Disease

View study

RECRUITINGNA

EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis.

NCT05597488

Cirrhosis Portal

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 4, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias

Inclusion Criteria

Exclusion Criteria

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis.

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

Remote Electrical Stimulation for Pain and Depression Treatment in Cirrhosis

OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD